FIELD: medicine.
SUBSTANCE: invention provides a therapeutic composition for treating and relieving diseases and disorders associated with fibrosis, containing: a carrier specified in a group consisting of a non-cationic polymer carrier, a liposomal carrier, a dendritic carrier, a nanomaterial carrier, a biostructural carrier and a micellar carrier; a targeting agent functionally bound to the carrier; the above targeting agent contains retinoid; and a therapeutic agent functionally bound to the carrier; the above therapeutic agent shows the therapeutic activity after the target organ or tissue delivery; the above therapeutic activity is specified in a group consisting of fibrosis inhibition in the above target organ or tissue.
EFFECT: higher selectivity and efficacy of the therapeutic agent delivery to the fibrosis involved organ or tissue.
39 cl, 10 ex, 9 dwg
Title | Year | Author | Number |
---|---|---|---|
IMAGING AGENTS FOR FIBROUS DISEASES | 2009 |
|
RU2596495C2 |
COMPOUNDS FOR TARGETED DELIVERY OF MEDICINE AND ENHANCED SIPHK ACTIVITY | 2012 |
|
RU2632888C2 |
COMPOUNDS FOR TARGETED DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | 2012 |
|
RU2769872C2 |
OXYGEN ABSORBING COMPOSITIONS | 2013 |
|
RU2640536C2 |
LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | 2013 |
|
RU2658007C2 |
RNA PARTICLES INCLUDING POLYSARCOZINE | 2019 |
|
RU2792644C2 |
USING ALPHA 2 ADRENERGIC RECEPTOR AGONISTS FOR TREATING OR PREVENTING PSORIASIS | 2010 |
|
RU2538729C2 |
ANTIBACTERIAL COMPOSITION FOR ORAL USE AND PREVENTION OF DENTAL DEPOSIT FORMATION AND COMPOUND | 1996 |
|
RU2170079C2 |
AGENT FOR TREATING RENAL FIBROSIS | 2011 |
|
RU2711531C2 |
METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY | 2012 |
|
RU2647476C2 |
Authors
Dates
2014-01-27—Published
2008-09-12—Filed